Basic and clinical immunology of Siglecs

Annals of the New York Academy of Sciences

Volumn 1143, Issue , 2008, Pages 61-82

  Von Gunten, Stephan ^a   Bochner, Bruce S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

Human; ITAM; ITIM; Lectin; Leukocyte; Mouse; Sialic acid; Siglec

Indexed keywords

CD 22 PROTEIN; CD 33 PROTEIN; CD33 ANTIGEN; CELL SURFACE PROTEIN; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; LIGAND; MYELIN ASSOCIATED GLYCOPROTEIN; PERVANADATE; SIALOADHESIN; SIGLEC 10 PROTEIN; SIGLEC 11 PROTEIN; SIGLEC 12 PROTEIN; SIGLEC 13 PROTEIN; SIGLEC 14 PROTEIN; SIGLEC 15 PROTEIN; SIGLEC 5 PROTEIN; SIGLEC 6 PROTEIN; SIGLEC 7 PROTEIN; SIGLEC 8 PROTEIN; SIGLEC 9 PROTEIN; SIGLEC E PROTEIN; SIGLEC F PROTEIN; SIGLEC G PROTEIN; SIGLEC H PROTEIN; SIGLEC L1 PROTEIN; SIGLEC XII PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL IMMUNOLOGY; CLINICAL TRIAL; HEMATOPOIETIC CELL; HUMAN; IMMUNOGLOBULIN GENE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

MURINAE;

EID: 56549099820     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1443.011     Document Type: Review

References (165)

1. Crocker, P.R. et al. 1998. Siglecs: a family sialic-acid binding lectins. Glycobiology 8 : v vi.
2. Varki, A. & T. Angata. 2006. Siglecs - the major sub-family of I-type lectins. Glycobiology 16 : 1R 27R.
3. Brinkman-Van der Linden, E.C. et al. 2007. Human-specific expression of Siglec-6 in the placenta. Glycobiology 17 : 922 931.
4. Angata, T., N.M. Varki & A. Varki. 2001. A second uniquely human mutation affecting sialic acid biology. J. Biol. Chem. 276 : 40282 40287.
5. Angata, T. et al. 2004. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc. Natl. Acad. Sci. USA 101 : 13251 13256.
6. Aizawa, H. et al. 2003. Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). Genomics 82 : 521 530.
7. Zhang, J.Q. et al. 2004. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur. J. Immunol. 34 : 1175 1184.
8. Tateno, H., P.R. Crocker & J.C. Paulson. 2005. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 15 : 1125 1135.
9. Hoffmann, A. et al. 2007. Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat. Immunol. 8 : 695 704.
10. Nguyen, D.H. et al. 2006. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA 103 : 7765 7770.
11. Zhang, M. et al. 2007. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109 : 4280 4287.
12. Paulson, J.C., O. Blixt & B.E. Collins. 2006. Sweet spots in functional glycomics. Nat. Chem. Biol. 2 : 238 248.
13. Crocker, P.R., J.C. Paulson & A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7 : 255 266.
14. Aizawa, H., J. Plitt & B.S. Bochner. 2002. Human eosinophils express two siglec-8 splice variants. J. Allergy Clin. Immunol. 109 : 176.
15. Avril, T. et al. 2006. Negative regulation of leucocyte functions by CD33-related siglecs. Biochem. Soc. Trans. 34 : 1024 1027.
16. Crocker, P.R. et al. 1998. Siglecs: a family of sialic-acid binding lectins. Glycobiology 8 : v vi.
17. Crocker, P.R. & A. Varki. 2001. Siglecs in the immune system. Immunology 103 : 137 145.
18. Crocker, P.R. & A. Varki. 2001. Siglecs, sialic acids and innate immunity. Trends Immunol. 22 : 337 342.
19. Crocker, P.R. 2002. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr. Opin. Struct. Biol. 12 : 609 615.
20. Crocker, P.R. 2005. Siglecs in innate immunity. Curr. Opin. Pharmacol. 5 : 431 437.
21. Collins, B.E. & J.C. Paulson. 2004. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr. Opin. Chem. Biol. 8 : 617 625.
22. Altheide, T.K. et al. 2006. System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents: Evidence for two modes of rapid evolution. J. Biol. Chem. 281 : 25689 25702.
23. Bock, N. & S. Kelm. 2006. Binding and inhibition assays for Siglecs. Methods Mol. Biol. 347 : 359 375.
24. von Gunten, S. & H.U. Simon. 2006. Sialic acid binding immunoglobulin-like lectins may regulate innate immune responses by modulating the life span of granulocytes. Faseb J. 20 : 601 605.
25. Varki, A. 2007. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 446 : 1023 1029.
26. Varki, N.M. & A. Varki. 2007. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab. Invest. 87 : 851 857.
27. McMillan, S.J. & P.R. Crocker. 2008. CD33-related sialic-acid-binding immunoglobulin-like lectins in health and disease. Carbohydr. Res. 343 : 2050 2056.
28. Crocker, P.R. et al. 1991. Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. Embo. J. 10 : 1661 1669.
29. Munday, J., H. Floyd & P.R. Crocker. 1999. Sialic acid binding receptors (siglecs) expressed by macrophages. J. Leukoc. Biol. 66 : 705 711.
30. Hartnell, A. et al. 2001. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 97 : 288 296.
31. McWilliam, A.S., P. Tree & S. Gordon. 1992. Interleukin 4 regulates induction of sialoadhesin, the macrophage sialic acid-specific receptor. Proc. Natl. Acad. Sci. USA 89 : 10522 10526.
32. Van Den Berg, T.K. et al. 1996. Regulation of sialoadhesin expression on rat macrophages. Induction by glucocorticoids and enhancement by IFN-beta, IFN-gamma, IL-4, and lipopolysaccharide. J. Immunol. 157 : 3130 3138.
33. Kirchberger, S. et al. 2005. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J. Immunol. 175 : 1145 1152.
34. York, M.R. et al. 2007. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum. 56 : 1010 1020.
35. Blixt, O. et al. 2003. Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J. Biol. Chem. 278 : 31007 31019.
36. Van Den Berg, T.K. et al. 2001. Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1). J. Immunol. 166 : 3637 3640.
37. Nath, D. et al. 1999. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 98 : 213 219.
38. Vanderheijden, N. et al. 2003. Involvement of sialoadhesin in entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages. J. Virol. 77 : 8207 8215.
39. Delputte, P.L. et al. 2007. Porcine arterivirus attachment to the macrophage-specific receptor sialoadhesin is dependent on the sialic acid-binding activity of the N-terminal immunoglobulin domain of sialoadhesin. J. Virol. 81 : 9546 9550.
40. Jones, C., M. Virji & P.R. Crocker. 2003. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol. Microbiol. 49 : 1213 1225.
41. Monteiro, V.G. et al. 2005. Increased association of Trypanosoma cruzi with sialoadhesin positive mice macrophages. Parasitol Res. 97 : 380 385.
42. Biesen, R. et al. 2008. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum. 58 : 1136 1145.
43. Pulliam, L., B. Sun & H. Rempel. 2004. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. J. Neuroimmunol. 157 : 93 98.
44. Van Der Kuyl, A.C. et al. 2007. Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS ONE 2 : e257. doi :.
45. Ip, C.W. et al. 2007. Sialoadhesin deficiency ameliorates myelin degeneration and axonopathic changes in the CNS of PLP overexpressing mice. Neurobiol. Dis. 25 : 105 111.
46. Kobsar, I. et al. 2006. Attenuated demyelination in the absence of the macrophage-restricted adhesion molecule sialoadhesin (Siglec-1) in mice heterozygously deficient in P0. Mol. Cell Neurosci. 31 : 685 691.
47. Jiang, H.R. et al. 2006. Sialoadhesin promotes the inflammatory response in experimental autoimmune uveoretinitis. J. Immunol. 177 : 2258 2264.
48. Oetke, C. et al. 2006. Sialoadhesin-deficient mice exhibit subtle changes in B- and T-cell populations and reduced immunoglobulin M levels. Mol. Cell Biol. 26 : 1549 1557.
49. Tedder, T.F., J.C. Poe & K.M. Haas. 2005. CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction. Adv. Immunol. 88 : 1 50.
50. Nitschke, L. 2005. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr. Opin. Immunol. 17 : 290 297.
51. Wakabayashi, C. et al. 2002. A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298 : 2392 2395.
52. Kimura, N. et al. 2007. Human B-lymphocytes express alpha2-6-sialylated 6-sulfo-N-acetyllacto-samine serving as a preferred ligand for CD22/Siglec-2. J. Biol. Chem. 282 : 32200 32207.
53. Onodera, T. et al. 2008. CD22 regulates time course of both B cell division and antibody response. J. Immunol. 180 : 907 913.
54. Poe, J.C. et al. 2004. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat. Immunol. 5 : 1078 1087.
55. Ghosh, S., C. Bandulet & L. Nitschke. 2006. Regulation of B cell development and B cell signalling by CD22 and its ligands alpha2,6-linked sialic acids. Int. Immunol. 18 : 603 611.
56. Collins, B.E. et al. 2006. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat. Immunol. 7 : 199 206.
57. Steinfeld, S.D. & P. Youinou. 2006. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin. Biol. Ther. 6 : 943 949.
58. Leonard, J.P. & D.M. Goldenberg. 2007. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26 : 3704 3713.
59. Andrews, R.G., B. Torok-Storb & I.D. Bernstein. 1983. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62 : 124 132.
60. Griffin, J.D. et al. 1984. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res. 8 : 521 534.
61. Peiper, S.C., R.A. Ashmun & A.T. Look. 1988. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood 72 : 314 321.
62. Freeman, S.D. et al. 1995. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85 : 2005 2012.
63. Yokoi, H. et al. 2006. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy 61 : 769 776.
64. Biedermann, B. et al. 2007. Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. Leuk. Res. 31 : 211 220.
65. von Gunten, S. et al. 2005. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 106 : 1423 1431.
66. Andrews, R.G. et al. 1986. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 68 : 1030 1035.
67. Robertson, M.J. et al. 1992. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 79 : 2229 2236.
68. Valent, P. et al. 1989. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73 : 1778 1785.
69. Valent, P. et al. 1990. Further characterization of surface membrane structures expressed on human basophils and mast cells. Int. Arch. Allergy Appl. Immunol. 91 : 198 203.
70. Valent, P. & P. Bettelheim. 1992. Cell surface structures on human basophils and mast cells. Biochemical and functional characterization. Adv. Immunol. 52 : 333 423.
71. Taylor, V.C. et al. 1999. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem. 274 : 11505 11512.
72. Ulyanova, T. et al. 1999. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur. J. Immunol. 29 : 3440 3449.
73. Paul, S.P. et al. 2000. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 96 : 483 490.
74. Walter, R.B. et al. 2008. ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. J. Leukoc. Biol. 83 : 200 211.
75. Vitale, C. et al. 1999. Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc. Natl. Acad. Sci. USA 96 : 15091 15096.
76. Vitale, C. et al. 2001. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc. Natl. Acad. Sci. USA 98 : 5764 5769.
77. Balaian, L., R.K. Zhong & E.D. Ball. 2003. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp. Hematol. 31 : 363 371.
78. Ferlazzo, G. et al. 2000. Engagement of CD33 surface molecules prevents the generation of dendritic cells from both monocytes and CD34+ myeloid precursors. Eur. J. Immunol. 30 : 827 833.
79. Lajaunias, F., J.M. Dayer & C. Chizzolini. 2005. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur. J. Immunol. 35 : 243 251.
80. Orr, S.J. et al. 2007. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 109 : 1061 1068.
81. Walter, R.B. et al. 2008. Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. Traffic 9 : 267 279.
82. Grobe, K. & L.D. Powell. 2002. Role of protein kinase C in the phosphorylation of CD33 (Siglec-3) and its effect on lectin activity. Blood 99 : 3188 3196.
83. Linenberger, M.L. 2005. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19 : 176 182.
84. Pagano, L. et al. 2007. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 26 : 3679 3690.
85. Tsimberidou, A.M. et al. 2006. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br. J. Haematol. 132 : 398 409.
86. Sievers, E.L. 2000. Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Curr. Opin. Oncol. 12 : 30 35.
87. Sievers, E.L. 2001. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin. Biol. Ther. 1 : 893 901.
88. Legrand, O. et al. 2000. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 96 : 870 877.
89. Bross, P.F. et al. 2001. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid. Leukemia Clin. Cancer Res. 7 : 1490 1496.
90. Tchilian, E.Z. et al. 1994. Molecular cloning of two isoforms of the murine homolog of the myeloid CD33 antigen. Blood 83 : 3188 3198.
91. Brinkman-Van der Linden, E.C. et al. 2003. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol. Cell Biol. 23 : 4199 4206.
92. Vyas, A.A. et al. 2002. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc. Natl. Acad. Sci. USA 99 : 8412 8417.
93. Quarles, R.H. 2007. Myelin-associated glycoprotein (MAG): past, present and beyond. J. Neurochem. 100 : 1431 1448.
94. Kursula, P. 2008. Structural properties of proteins specific to the myelin sheath. Amino Acids 34 : 175 185.
95. Mehta, N.R. et al. 2007. Gangliosides and Nogo receptors independently mediate myelin-associated glycoprotein inhibition of neurite outgrowth in different nerve cells. J. Biol. Chem. 282 : 27875 27886.
96. Sun, J. et al. 2004. Myelin-associated glycoprotein (Siglec-4) expression is progressively and selectively decreased in the brains of mice lacking complex gangliosides. Glycobiology 14 : 851 857.
97. Swanson, B.J. et al. 2007. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4 a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 67 : 10222 10229.
98. Pan, B. et al. 2005. Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp. Neurol. 195 : 208 217.
99. Cornish, A.L. et al. 1998. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood 92 : 2123 2132.
100. Connolly, N.P., M. Jones & S.M. Watt. 2002. Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions. Br. J. Haematol. 119 : 221 238.
101. Ghannadan, M. et al. 2002. Detection of novel CD antigens on the surface of human mast cells and basophils. Int. Arch. Allergy Immunol. 127 : 299 307.
102. Virgo, P. et al. 2003. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias. Br. J. Haematol. 123 : 420 430.
103. Erickson-Miller, C.L. et al. 2003. Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes. Exp. Hematol. 31 : 382 388.
104. Hampton, M.B., A.J. Kettle & C.C. Winterbourn. 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92 : 3007 3017.
105. Winterbourn, C.C. et al. 2006. Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J. Biol. Chem. 281 : 39860 39869.
106. Rapoport, E.M. et al. 2005. Sialoside-binding macrophage lectins in phagocytosis of apoptotic bodies. Biochemistry (Mosc). 70 : 330 338.
107. Avril, T. et al. 2005. Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation. J. Biol. Chem. 280 : 19843 198451.
108. Gunnarsson, P. et al. 2007. The acute-phase protein alpha 1-acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin-like lectins (siglecs). Faseb J. 21 : 4059 4069.
109. Angata, T. et al. 2006. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. Faseb J. 20 : 1964 1973.
110. Takei, Y. et al. 1997. Molecular cloning of a novel gene similar to myeloid antigen CD33 and its specific expression in placenta. Cytogenet Cell Genet. 78 : 295 300.
111. Patel, N. et al. 1999. OB-BP1/Siglec-6. a leptin- and sialic acid-binding protein of the immunoglobulin superfamily. J. Biol. Chem. 274 : 22729 22738.
112. Florian, S. et al. 2006. Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy 61 : 1054 1062.
113. Falco, M. et al. 1999. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J. Exp. Med. 190 : 793 802.
114. Nicoll, G. et al. 1999. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274 : 34089 34095.
115. Angata, T. & A. Varki. 2000. Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology 10 : 431 438.
116. Ikehara, Y., S.K. Ikehara & J.C. Paulson. 2004. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J. Biol. Chem. 279 : 43117 43125.
117. Yamaji, T. et al. 2002. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J. Biol. Chem. 277 : 6324 6332.
118. Avril, T. et al. 2004. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J. Immunol. 173 : 6841 6849.
119. Avril, T. et al. 2006. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression. J. Leukoc. Biol. 80 : 787 796.
120. Orr, S.J. et al. 2007. SOCS3 Targets Siglec 7 for Proteasomal Degradation and Blocks Siglec 7-mediated Responses. J. Biol. Chem. 282 : 3418 3422.
121. Vitale, C. et al. 2001. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells. Proc. Natl. Acad. Sci. USA. 98 : 5764 5769.
122. Scott, C.J. et al. 2008. Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles. Pharm. Res. 25 : 135 146.
123. Kikly, K.K. et al. 2000. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells and basophils. J. Allergy Clin. Immunol. 105 : 1093 1100.
124. Floyd, H. et al. 2000. Siglec-8: a novel eosinophil-specific member of the immunoglobulin superfamily. J. Biol. Chem. 275 : 861 866.
125. Guo, J.P. et al. 2007. Siglec-8 and Siglec-F: inhibitory receptors on eosinophils, basophils and mast cells. Allergy Clin. Immunol. Inter. J. World Allergy Org. 19 : 54 59.
126. Von Gunten, S. & B.S. Bochner. 2008. Expression and function of Siglec-8 in human eosinophils, basophils and mast cells. In Allergy Frontiers: From Epigenetics to Future Perspectives. R. Pawankar, S. Holgate & L.J. Rosenwasser, Eds. Springer-Verlag. Tokyo (in press).
127. Foussias, G., G.M. Yousef & E.P. Diamandis. 2000. Molecular characterization of a Siglec-8 variant containing cytoplasmic tyrosine-based motifs, and mapping of the Siglec-8 gene. Biochem. Biophys. Res. Commun. 278 : 775 781.
128. Munday, J. et al. 2001. Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. Biochem. J. 355 : 489 497.
129. Nutku, E. et al. 2004. Expression and function of Siglec-8 isoforms in human eosinophils, basophils and mast cells. In Allergy Frontiers and Futures, Proceedings of the 24th Symposium of the Collegium Internationale Allergologicum. J. Bienenstock, J. Ring & A.G. Togias, Eds. : 130 132. Hogrefe and Huber. Cambridge, Massachusetts.
130. Nutku, E. et al. 2003. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101 : 5014 5020.
131. Nutku, E., S.A. Hudson & B.S. Bochner. 2005. Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury. Biochem. Biophys. Res. Commun. 336 : 918 924.
132. von Gunten, S. et al. 2007. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J. Allergy Clin. Immunol. 119 : 1005 1011.
133. Nutku-Bilir, E., S.A. Hudson & B.S. Bochner. 2008. Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways. Am. J. Respir. Cell Mol. Biol. 38 : 121 124.
134. Landwehr, L.P. et al. 1998. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 114 : 1349 1356.
135. O'Donnell, B.F. et al. 1998. Intravenous immunoglobulin in autoimmune chronic urticaria. Br. J. Dermatol. 138 : 101 106.
136. Tsurikisawa, N. et al. 2004. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann. Allergy Asthma Immunol. 92 : 80 87.
137. Yokoi, H. et al. 2008. Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by Siglec-8 engagement. J. Allergy Clin. Immunol. 121 : 499 505.
138. Stevens, W.W. et al. 2007. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J. Immunol. Methods. 327 : 63 74.
139. Ohnmacht, C. et al. 2007. Analysis of eosinophil turnover in vivo reveals their active recruitment to and prolonged survival in the peritoneal cavity. J. Immunol. 179 : 4766 4774.
140. Voehringer, D., N. van Rooijen & R.M. Locksley. 2007. Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. J. Leukoc. Biol. 81 : 1434 1444.
141. Kearley, J. et al. 2007. Anti-Siglec-F antibody treatment during allergen-induced airway inflammation reduces eosinophil numbers but has no effect on airway hyperreactivity in vivo. Am. J. Respir. Crit. Care Med. 175 : A690 (abstr.).
142. Zimmermann, N. et al. 2008. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy. 63 : 1156 1163.
143. Bochner, B.S. et al. 2005. Glycan array screening reveals a candidate ligand for Siglec-8. J. Biol. Chem. 280 : 4307 4312.
144. Rapoport, E.M. et al. 2006. Probing sialic acid binding Ig-like lectins (siglecs) with sulfated oligosaccharides. Biochemistry (Mosc). 71 : 496 504.
145. Tateno, H. et al. 2007. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol. Cell Biol. 27 : 5699 5710.
146. Guo, J. et al. 2007. Ligands for Siglec-8 and Siglec-F: binding characteristics and tissue distribution. J. Allergy Clin. Immunol. 119 : S299 (abstr.).
147. Angata, T. & A. Varki. 2000. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. J. Biol. Chem. 275 : 22127 22135.
148. Zhang, J.Q. et al. 2000. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J. Biol. Chem. 275 : 22121 22126.
149. Yamaji, T. et al. 2005. Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs. Glycobiology 15 : 667 676.
150. von Gunten, S. et al. (2006. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108 : 4255 4259.
151. Buenz, E.J. & C.L. Howe. 2007. Appropriate use of intravenous immunoglobulin in neonatal neutropenia. J. Perinatol. 27 : 196 197 author reply 197.
152. Yu, Z. et al. 2001. mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain- containing protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. J. 353 : 483 492.
153. Li, N. et al. 2001. Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells. J. Biol. Chem. 276 : 28106 28112.
154. Whitney, G. et al. 2001. A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. Eur. J. Biochem. 268 : 6083 6096.
155. Yousef, G.M. et al. 2001. Molecular characterization, tissue expression, and mapping of a novel Siglec-like gene (SLG2) with three splice variants. Biochem. Biophys. Res. Commun. 284 : 900 910.
156. Kitzig, F. et al. 2002. Cloning of two new splice variants of Siglec-10 and mapping of the interaction between Siglec-10 and SHP-1. Biochem. Biophys. Res. Commun. 296 : 355 362.
157. Whitney, G. et al. 2001. A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. Eur. J. Biochem. 268 : 6083 6096.
158. Azuma, C. et al. 1986. Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue. Nucleic Acids Res. 14 : 9149 9158.
159. Angata, T. et al. 2002. Cloning and characterization of human Siglec-11. A recently evolved signaling that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J. Biol. Chem. 277 : 24466 24474.
160. Angata, T. et al. 2007. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 17 : 838 846.
161. Blasius, A.L. & M. Colonna. 2006. Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trends Immunol. 27 : 255 260.
162. Blasius, A.L. et al. 2006. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 107 : 2474 2476.
163. Zhang, J. et al. 2006. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107 : 3600 3608.
164. Campanero-Rhodes, M.A. et al. 2006. Carbohydrate microarrays reveal sulphation as a modulator of siglec binding. Biochem. Biophys. Res. Commun. 344 : 1141 1146.
165. Cao, H. et al. 2008. SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans. Eur. J. Immunol. 38 : 2303 2315.